Friday 31 July - Scientific Sessions
Friday’s program will highlight important advances shaping the future of breast cancer research and treatment. Session 3: Translational Research will showcase cutting-edge studies that bridge laboratory discovery and clinical application, highlighting how scientific insights are being translated into improved therapies and patient outcomes.
The day will conclude with Session 4: Early Breast Cancer, focusing on the latest research and clinical developments in the treatment and management of early-stage disease. Presentations will explore emerging evidence, evolving treatment strategies, and approaches aimed at improving outcomes for people diagnosed with breast cancer. Together, these sessions will provide delegates with valuable insights into the science and clinical practice driving progress across the breast cancer care continuum.
Introduction to Translational Research Session
Challenges in Classification of LCIS and ILC
Sunil Lakhani
Molecular Talk on Lobular Cancers
Amy McCart Reed
Management of ILC Metastases
Nicola Lowrey
Morning Tea Break
Welcome Back to Session
Robert Sutherland Award Presentation by Cheryl Sutherland
AllClear Study
Rachel Dear
The Seeds of Cancer Relapse in the Skeleton
Peter Croucher
ACTIVA: The ALLCLEAR Clinical Trial Platform
Nick Zdenkowski
Lunch Break & Pfizer Sponsored Symposium
Introduction to Early Breast Cancer Session
Should SNB be Omitted in the Majority of Patients Over 50 with Clinical Stage 1 ER+/HER2-ve Cancer
Bruce Mann (no), debate with Jana de Boniface (yes).
Bruce Mann
Jana de Boniface
Window of Opportunity Studies - Particularly Pre-Operative Endocrine Therapy and the Influence on the Need for Chemotherapy in Early ER-Positive Breast Cancer
Nadia Harbeck
Afternoon Tea Break
Welcome Back to Session
Current Status of RT Optimisation for Early Stage Breast Cancer
Julia White
Bringing Novel Agents into the Early Stage Setting
Sara Hurvitz
Closed of Scientific Session & 2026 ASM
Bruce Mann